Methemoglobinemia is a life-threatening disease that must be treated promptly and efficiently. It is diagnosed by performing different diagnostic tests. Methylene blue is being used as a vital treatment for methemoglobinemia, but does not have proven efficacy in patient with G6PD deficiency. Here in the case study, we have reported the case of a 19-year-old male patient with an alleged history of industrial exposure to nitrobenzene (aniline dye exposure in textile factories), who developed methemoglobinemia, for which he was treated with methylene blue. However, there was no improvement in his symptoms. On the other hand, there was a drop in his hemoglobin level with worsening of kidney function due to hemolysis of red blood cells. On further examination, the patient was found to be G6PD deficient. The patient was provided with the only available method of treatment consisting of repeated blood transfusions and ascorbic acid with dialysis to which the patient responded, started recovering and after 26 days of intensive treatment, he was discharged from the hospital.

e19546 Background: Plasmablastic lymphoma (PBL), a variant of diffuse large B-cell lymphoma, is a rare and aggressive malignancy. Minimal guidelines exist for its diagnosis and standard of care. Hence, we studied the epidemiological characteristics and survival variables of PBL patients by using the SEER 20 database. Methods: A total of 229 cases of PBL (WHO ICD-O-3 codes 9735/3) were identified between 2000 and 2015, after excluding 66 cases with unknown survival time or no microscopic confirmation. The epidemiological characteristics and the survival variables included were age, gender, ethnicity, Ann Arbor stage, B-symptoms, and site. The overall 5-year survival (OS), cause-specific 5-year survival (CSS), and cause-specific survival plots across different strata were plotted using the Kaplan Meier Method. The analysis was done using the Cox proportional hazard regression model (p < 0.05). Results: The incidence of PBL was 0.03 per 100,000 cases. It was more common in adults less than 60 years (61.57%), males (79.04%), and White ethnicity (72.49 %). There were more cases of patients with advanced Ann Arbor stages (3 or 4) PBL (52.84%), although some patients (5.68%) had unknown staging. There were 55.02% of extranodal cases, and 28.38% of patients had B-symptoms. The OS was 36.55%, and the CSS was 46.5%. CSS did not differ significantly based on age, race, or gender. However, the absence of B-symptoms was associated with better CSS (HR: 0.654, 95% CI: 0.455-0.941, p: 0.022). Nodal involvement (HR: 1.553, 95% CI: 1.135-2.124, p: 0.006) and advanced stages 3 or 4 (HR: 1.414, 95% CI: 1.018-1.962, p: 0.038) were also linked to a poor CSS. Conclusions: PBL patients with a primary nodal involvement and advanced staging (3 or 4) had poor CSS, and the absence of B-symptoms was associated with a better outcome. Age, gender, and ethnicity had no discernible effects on survival. We did not include therapeutic options in our study, and hence, further studies analyzing the impact of treatment options on PBL survival can be conducted.[Table: see text]